Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: Track, Go-Gold, TheHungryHippo, BluSkies, GoldenMind, Rdy1
Search This Board: 
Last Post: 8/20/2017 11:52:25 PM - Followers: 823 - Board type: Free - Posts Today: 0


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Quarterly Report (10-q) 08/08/2017 04:04:37 PM
USRM News: Quarterly Report (10-q) 05/02/2017 04:06:21 PM
USRM News: Significant Updates on the Following Companies and New Coverage 04/20/2017 09:00:00 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:49:04 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:47:59 AM
#76343  Sticky Note "This bill, the Right to Try Act, will TheHungryHippo 08/14/17 01:46:06 AM
#76022  Sticky Note CEO Blog: A Historic Quarter for USSC Track 08/10/17 04:35:12 PM
#75686  Sticky Note US STEM CELL UPDATE 8/8/2017 8:14:40 pm Eastern GoldenMind 08/08/17 08:14:43 PM
#72621  Sticky Note MYOCELL CLINICAL TRIALS, SIX PATIENT DEATHS !! Hornet Driver 06/29/17 10:22:27 AM
#71576  Sticky Note QUOTE LOL, Hippo DD info found here! sdave2002 06/22/17 03:42:36 PM
#77195   So, those kids had it figured out Work Harder 08/20/17 11:52:24 PM
#77193   If those 2000 people spend $2,000 to $4,000 KRex0969 08/20/17 11:27:09 PM
#77192   USRM chart:~~~ Trigger setup and Falling Wedge. tothe 08/20/17 11:17:30 PM
#77190   Vetbiologics sells these kits all around the world! The Staypositive1 08/20/17 11:02:28 PM
#77189   About 2000 people attended. Now you know. GoldenMind 08/20/17 10:56:13 PM
#77188   Quote LOL, "Kristin Comella presents at RAAD Festival Hornet Driver 08/20/17 10:46:39 PM
#77187   Kristin Comella presents at RAAD Festival 2017! KRex0969 08/20/17 10:41:57 PM
#77184   Over 7000 treated patients with a 99%success rate! Staypositive1 08/20/17 10:24:01 PM
#77183   ASSETS  $283k Jun 2016  $413k Sep 2016  $427k Dec 2016  $1385k Mar Staypositive1 08/20/17 10:22:02 PM
#77182   Dear Shareholders and Friends, It has been a historic Staypositive1 08/20/17 10:20:12 PM
#77181   Kristin Comella, U.S. Stem Cell’s CSO, Co-Authors Paper Staypositive1 08/20/17 10:14:08 PM
#77180   COURT "testimonials" BLIND LADIES !! Hornet Driver 08/20/17 10:13:39 PM
#77179   Article: BEWARE SCAM TRIALS..LOOK WHO's LISTED !! Hornet Driver 08/20/17 10:11:31 PM
#77178   Lets see what next week brings here MOCKBA 08/20/17 10:10:13 PM
#77177   Reuters: UNPROVEN CELL TREATMENT CLINICS ! Hornet Driver 08/20/17 10:09:54 PM
#77176   Ceo aug blog Dear Shareholders and Friends, It has been Staypositive1 08/20/17 09:59:41 PM
#77175   Harris will probably live to a 100! Staypositive1 08/20/17 09:57:30 PM
#77174   Barbara is a real trooper! Staypositive1 08/20/17 09:56:29 PM
#77173   How can you argue with results like this. Staypositive1 08/20/17 09:55:28 PM
#77172   FDA is hearing our voices! Staypositive1 08/20/17 09:54:12 PM
#77171   Myocell NO LONGER EVEN UNDER PATENT, LOL !! Hornet Driver 08/20/17 09:42:55 PM
#77170   CEO Blog: A Historic Quarter for USSC sdave2002 08/20/17 09:12:47 PM
#77169   GACP TERMINATED $5 mil INVESTMENT AGREEMENT, LOL !!! Hornet Driver 08/20/17 08:50:16 PM
#77168   STILL...GOING CONCERN LIQUIDITY WARNINGS !! Hornet Driver 08/20/17 08:48:56 PM
#77167   Yep Rocketrider, this is about to lift off Staypositive1 08/20/17 07:33:53 PM
#77166   Good post dude !! Totally resonate with you BurningMan 08/20/17 06:52:51 PM
#77165   Yeah doc!! Usrmstrong!! rocketRider 08/20/17 06:39:22 PM
#77164   I like you !!! You're attitude is amazing BurningMan 08/20/17 06:29:35 PM
#77163   And that post has the luxury of being docprep 08/20/17 06:28:55 PM
#77162   Only weeks away from September! Big things going on. Leggy 08/20/17 06:03:51 PM
#77161   Exciting times ahead! Great Long here$$$$ TooYoungToDie 08/20/17 05:58:15 PM
#77160   If it's needed. We could possibly sell BurningMan 08/20/17 05:57:16 PM
#77159   Yes fda guidelines coming in September, RMAT TooYoungToDie 08/20/17 05:54:16 PM
#77158   No doubt ! MYOCELL is a great product BurningMan 08/20/17 05:52:46 PM
#77157   New highs coming by November LIFECHANGER$$$$$ TooYoungToDie 08/20/17 05:49:50 PM
#77156   Not if you factor q over q improvements BurningMan 08/20/17 03:06:42 PM
#77155   Yep back up to .20 coming in next Joeymc77 08/20/17 03:06:40 PM
#77154   At least. This valuation is not appropiate if GoldenMind 08/20/17 01:52:40 PM
#77153   The pump articles are coming back??? Do we 0mn1 08/20/17 01:51:17 PM
#77152   Friday's price and volume action was supposed to rancher64 08/20/17 12:47:47 PM
#77151   Hey Texas BYOSC !!!!!!!! Jake731 08/20/17 12:24:18 PM
#77150   Good look at the growth : BurningMan 08/20/17 10:40:36 AM
#77149   True that ! You got good feedback from BurningMan 08/20/17 10:22:10 AM
#77148   Expecting an increase going into Trump signing the BurningMan 08/20/17 10:20:57 AM
#77147   Wise words from wise man lol. Sticky this. docprep 08/20/17 10:19:58 AM
#77146   All notes paid and big catalysts in the BurningMan 08/20/17 09:49:59 AM
#77145   Great to see a green day but not Wolfe64 08/20/17 09:44:49 AM
#77144 BurningMan 08/20/17 09:29:00 AM
#77143   .0375 target close for monday Afterhoursearnings3 08/20/17 08:46:09 AM
#77142   USRM on the move up now folks... Summer BoilerRoom 08/20/17 04:14:39 AM